Since loss of CREB3L1 is prevalent in ~ 75% of TNBCs and this loss contributes to metastatic breast cancer cell properties11,15, we focused on identifying compounds most cytotoxic towards the more metastatic CREB3L1-deficient TNBCs. This evidence concerns the gene CREB3L1 and breast cancer.